Related Experiment Video
Updated: Dec 9, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Radiotherapy in the management of glottic squamous cell carcinoma
William M Mendenhall1, Primož Strojan2, Anne W M Lee3
1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.
Introduction:
Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC).
Methods:
A concise review of the pertinent literature.
Results:
RT cure rates are Tis- T1N0, 90% to 95%; T2N0, 70% to 80%; low-volume T3-T4a, 65% to 70%. Concomitant cisplatin is given for T3-T4a SCCs. Severe complications occur in 1% to 2% for Tis-T2N0 and 10% for T3-T4a SCCs. Patients with high-volume T3-T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local-regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%.
Conclusions:
RT is a good treatment option for patients with Tis-T2N0 and low-volume T3-T4a glottic SCCs. Patients with higher volume T3-T4 cancers are best treated with surgery and postoperative RT.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
02:56Treatment Resistant Cancers